

SEROPREVALENCE OF HEPATITIS B AND C CO-INFECTIONS AMONG PREGNANT WOMEN ATTENDING BINGHAM UNIVERSITY TEACHING HOSPITAL JOS, NIGERIA

*¹Zakari. H., ¹Dawurum, D.S., ¹Ajang, A.Y., ¹Katmap S.R. and ²Adabara, U.N. ¹Department of Microbiology, Faculty of Natural Sciences University of Jos, Nigeria

²Department of Microbiology, Faculty of Sciences and technology, Federal University of Technology Minna, Nigeria.

Email: hashyz@yahoo.com.

(Received 28th May 2015; Accepted 21st September 2015)

ABSTRACT

Hepatitis B and C virus infections continue to be a major problem in developing countries, Nigeria inclusive. This study aimed to determine the sero-prevalence of Hepatitis B and C virus (HBV and HCV) among pregnant women attending ante-natal clinics in Bingham University Teaching Hospital (BUTH) Jos. Blood specimens were collected from 100 pregnant women and tested for hepatitis B and C virus using HBV and HCV one step rapid test strip (Diaspot Diagnostic, USA). Out of 100 subjects screened, 12(12.0%) and 3(3.0%) were positive for HBV and HCV respectively. No co-infection was observed among the pregnant women tested. The prevalence in relation to age shows that the infection was more prevalent among the age group 16-20 years and 21-25 years of age in the case of Hepatitis B with prevalence of 1(20.0%) and 3(20.0%) respectively while, 36-40 years in the case of hepatitis C with prevalence of 2(11.0%). The prevalence of the viruses in relation to the educational status of the subjects revealed that those with non- formal education had the highest prevalence of HBV with 1(16.7%) while those with MS.c had the highest prevalence for HCV with a total of 1(20.0%). However, the relationship was statistically non- significant ($P>0.005$). The prevalence of HBV in relation to trimester showed that those in second trimester had the highest with 4(12.0%) however, those in their third trimester had the highest prevalence of HCV with prevalence of 2(5.6%). In all, the difference was statistically not significant ($p>0.05$). In conclusion the study has shown that HBV and HCV are still prevalent among pregnant women in the study area. Therefore there is need for routine testing of all pregnant women at first and postnatal visit so that HBV and HCV positive mothers can receive prompt intervention.

INTRODUCTION

Hepatitis B virus (HBV) is a DNA virus of the family *Hepadnaviridae* and the causative agent of hepatitis B infection. It is 50 - 100 times more infectious than HIV and 10 times more infectious than hepatitis C virus (Pungpaong et al., 2007). Many carriers do not realize they are infected with the virus, thus it is referred to as a "silent killer" (Samuel et al., 2004). Hepatitis C virus is an RNA virus of the *Flaviviridae* family

and appears to have humans and chimpanzees as the only species susceptible to its infection (Isa, et al., 2016). Apart from being detected in blood, it has also been detected in semen (Cavallero et al., 2008) and saliva (Chen et al., 2006). HBV and HCV account for a substantial portion of liver diseases worldwide and infected individuals can remain asymptomatic for decades (Oluboyo et al., 2014).

Infections with the Hepatitis B virus (HBV) or the Hepatitis C virus (HCV) are public health problems and are highly endemic in the sub-Saharan Africa (Kemebradikumo and Isa, 2013). Hepatitis B is one of the world's most common and serious infectious diseases. It is estimated that more than one third of the world's population has been infected with the hepatitis B virus. About 5% of the populations are chronic carriers of hepatitis B virus, and nearly 25% of all carriers develop serious liver diseases. HBV infection causes more than one million deaths every year (WHO 2014).

Worldwide, there are about 350 million HBV carriers and 130 to 170 million people infected with HCV (Liu and Hou, 2006; Eke et al., 2011; WHO, 2011) with Nigeria classified among the group of countries endemic for HBV infection.

Viral hepatitis during pregnancy is associated with high risk of maternal complications (Kramvis and Kew, 2007). The minimum infectious dose is so low that such practices like sharing a tooth brush or a razor blade can transmit infection (Chang, 2008). HBV also shares similar routes of transmission with HIV (Willey et al., 2008). Perinatal transmission of this disease occurs if the mother has had acute Hepatitis B infection during late pregnancy, in the first postpartum or if the mother is a chronic HBsAg carrier (Levy et al., 1991). Hepatitis C transmission occurs predominantly around time of delivery and pregnancy (WHO, 1999).

Among pregnant women, chronic infection with HBV and HCV are often asymptomatic, and can lead to coagulation defects, postpartum haemorrhage, organ failure and high maternal mortality and poor outcomes of their newborns such as still births, neonatal deaths (NND), jaundice, anorexia (poor appetite), malaise, acute and chronic liver disease (liver cirrhosis) and hepatocellular carcinoma. Co-infection of HBV and HCV seems to result in more severe disease than either infection alone (Esan et al., 2014).

In Nigeria, the prevalence rates of HBV and HCV in pregnant women differ from one locality to another. Yakasai et. al. (2012) reported a prevalence of 7.9 and 7.6% of HBsAg among pregnant women and non-pregnant women respectively in Kano, Nigeria. Similarly Oladeinde et. al. (2013) reported a prevalence of 8 (2.2%) and 3 (0.8%) for HBV and HCV infections respectively among pregnant women in Benin City, Nigeria. HBV/HCV co-infection rate of 6.8% was obtained in Ado Ikit among pregnant women (Esan et al., 2014). The study was aimed at determining the seroprevalence of HBV and HCV among pregnant women attending antenatal clinic of Bingham University Teaching Hospital, Jos.

MATERIALS AND METHODS

Study Area

The study was carried out in Jos Plateau State Nigeria between April and June 2016. Plateau State is roughly located in the centre of Nigeria between Latitude 8°24'N and Longitude 9°56'North and 8°53'East. The altitude ranges from around 1,200 metres to a peak of about 1,829 metres above sea level. With an area of 391 square kilometers, the population was estimated to be 900,000 in 2006 according to National Population Commission, 2006 census. The city contains a vast number of public and private hospitals including Bingham University Teaching Hospital (BUTH). BUTH has a sizeable population of subjects, many social amenities, different wards and adequate emergency unit and antenatal care services making it suitable for the study.

Ethical Clearance and Consent of the participants

Ethical approval was sought and obtained from the Bingham University Teaching Hospital, Jos Plateau State before commencement of the study. Informed consent of the subjects was individually sought and obtained before the commencement of the study.

Study Population

The study population consisted of all consenting pregnant women (age 18 years and above) attending the antenatal clinic of the hospital. A total of 100 pregnant women were randomly selected and enrolled for the study and their identity was handled with confidentiality.

Data collection

Data was collected using a semi-structured interviewer administered questionnaire. It consisted of the following: socio-demographic (age, marital status, employment status and educational status) information on the participants' knowledge of the infection, and information on the predisposing factors of the infection (intravenous drug use, tattooing, use of sharp objects, blood transfusion, multiple sexual partners and history of vaccination).

Sample Collection

Five milliliters (5ml) of the blood was collected from each the participants through venipuncture and emptied into labeled sterile tubes without anticoagulant, allowed to clot and centrifuged at 1000-1500g for 10 minutes to obtain the serum. The serum aliquots were transferred to plain sterile sample bottles, labeled appropriately and stored at -20°C until ready for use.

Screening for Hepatitis B and C

One step HBsAg strip and One step HCV antigen strip. (DiaSpotDiagnostics, UK), a rapid chromatographic immunoassay for the qualitative detection of Hepatitis B surface antigen and HCV in serum/plasma were used separately to screen the participant's serum sample. The analysis was carried out following the manufacturer's instruction.

HBV and HCV screening Procedure

The test was carried out at room temperature (18 - 26°C). The test strips for HBV and HCV were removed from the foil pouch by tearing at the notch. The strips were separately immersed into the specimens with the arrow pointing towards the specimens and were removed after 10

seconds and placed on a flat clean, dry and non-absorbent surface. The results were read after 15 minutes and the procedure was repeated for all the specimens.

Visible rose = pink bands in both the control and the appropriate test region indicated a positive result for HBsAg and HCV in the specimen and visible rose = pink band only in the control region indicated a negative result.

Data analysis

Data obtained were entered in Statistical package for social Sciences version 20 to test for significant difference between variables using chi-square test. Statistical significance was determined at ($P < 0.05$) at 95% Confidence interval and results were recorded and tabulated.

RESULTS

Out of the 100 women recruited in this study, 12 (12.0%) were positive for HBV and 3 (3.0%) were positive for HCV, but, co-infection was not detected (Table 1). Table 2 depicts the seroprevalence of HBV and HCV in relation to age among the pregnant women. It shows that HBV infection was more prevalent (20%) each among individuals within the age group 16-20 years and 21-25 years respectively. The least prevalence was found within the age group 31-35 years. Similarly, HCV sero-positivity was 11.1% among individuals aged 36-40 years followed by individual aged 31-35 years with prevalence of 3.3%. Zero (0%) prevalence was recorded among other age groups. Statistically, there was no significant difference between age and prevalence of HBV and HCV ($P > 0.05$).

Table 3 shows the prevalence of hepatitis in relation to associated risk factors among the pregnant women. Of the 100 pregnant women recruited in this study, 22 admitted they had surgery of which 1 (4.5%) each was positive for HBV and HCV respectively. The remaining 78 participant who had no history of surgery had 11 (14.1%) and 2 (2.6%) prevalence of HBV and HCV respectively. Also, of the 100 pregnant women recruited in this study, four (4) had previous history of blood transfusion out of which 1 (25.0%) was positive for HBV. No

seropositivity was obtained for HCV. The remaining 96 who had no history of blood transfusion showed a prevalence of 11(11.5%) and 3(3.1%) for HBV and HCV respectively. The result also shows that none of the four (4) subjects who admitted to having more than one sexual partner were positive for HBV and HCV. Statistical analysis revealed no association ($p>0.05$) between prevalence and any of the associated risk factors.

Table 4 shows the sero-prevalence of HBV and HCV with respect to the level of education. The infections were more prevalent among those with SSCE(22.7%) and Postgraduate level of education (20.0%) for HBV and HCV respectively. However, HBV was not detected among those with pre-degree and postgraduate levels of education, while, HCV was equally not detected among those with degree.

The prevalence of HBV and HCV in relation to occupational status revealed that, those with non-formal occupation had the highest prevalence 50% for HBV while, no case was detected among housewives, applicants and students respectively. Only civil servants were positive for HCV with 5.7%. There is however no statistical association ($P>0.05$) between prevalence of the two infections and occupation (Table 5).

Table 6 shows the prevalence of HBV and HCV with respect to marital status. Seroprevalence was higher among the married with 12.4% and 3.1% for HBV and HCV respectively compared with 0.0% for the unmarried (single and widow). Statistically, there is no significant difference ($P>0.05$).

Seroprevalence of HBV in relation to age of pregnancy revealed that, those in the first and second trimester had the highest prevalence of 12.5%, while, the least prevalence was obtained among those in the third trimester (11.1%). For HCV, those in the third trimester had the highest prevalence 5.6%, while the infection was not detected among those in the first trimester.

There was no statistical association ($p>0.05$) Table 7.

Table 1: Sero-prevalence of HBV, HCV and Co-infection among Pregnant Women

Variables	No. screened	No. positive	Percentage (%)
Hepatitis B	100	12	12.0
Hepatitis C	100	3	3.0
HBV/HCV co-infection	100	0	0.0

Key: HBV = Hepatitis B virus. HCV = Hepatitis C virus.

DISCUSSION

The prevalence of hepatitis B and C infections varies in different parts of the world from country to country (Ephraim *et al.*, 2015). The overall prevalence of HBV among pregnant women in this study was 12% and HCV had a prevalence of 3.0% and there was no co-infection. The 12.0% prevalence of HBV recorded in this study is relatively high according to WHO criteria (WHO, 1999). The result is similar with the 12.5% and 3.6% prevalence for hepatitis B and C respectively among pregnant women in some part of Nigeria (Ugbebor, *et al.*, (2011)). There were higher prevalence rates of 15.8% for HBV in Maiduguri (Baba *et al.*, 1999), 21.8% in Ibadan (Otegbayo, *et al.*, 2003), 14.1% in Kano (Musa, *et al.*, 2015). A high prevalence of 17.3% was also reported in Burkino Faso (Collenberget *et al.*, 2006). However lower prevalence of 11% was recorded in Markurdi (Mbaawuga *et al.*, 2008), 2.19 % in Benin City (Onakewhor and Okonofua, 2008) and 8.3% in Zaria (Luka *et al.*, 2008). For HCV, a low prevalence of 3.0% was reported in this research when compared with the 14.9% reported in Kaduna (WHO, 2007). These variations may be related to socio-cultural practices, environmental factors, difference in the sensitivity of the test methods and sample size.

Table 2: Sero-prevalence of HBV and HCV Infection in Relation to Age among Pregnant Women

Age group (years)	No. screened	No. Positive (%)	HBV		HCV		
			χ^2	p-value	No. Positive (%)	χ^2	p-value
16-20	5	1(20.0)	1.824	0.573	0(0.0)	5.689	0.338
21-25	15	3(20.0)			0(0.0)		
26-30	29	3(10.3)			0(0.0)		
31-35	30	3(10.0)			1(3.3)		
36-40	18	2(11.1)			2(11.1)		
41-45	3	0(0.0)			0(0.0)		
Total	100	12(12.0)			3(3.0)		

Key: HBV = Hepatitis B virus, HCV = Hepatitis C virus.

Table 3: Sero-prevalence of HBV and HCV in Relation to Associated Risk Factors among Pregnant Women

Risk factors	No. screened	HBV		HCV			
		(%) Positivity	χ^2	p-value	% Positivity	χ^2	p-value
History of surgery							
Yes	22	1(4.5)	1.484	0.223	1(4.5)	0.231	0.630
No	78	11(14.1)			2(2.6)		
Blood transfusion							
Yes	04	1(25.0)	0.667	0.414	0(0.0)	0.129	0.720
No	96	11(11.5)			3(3.1)		
Sex partner							
One	96	12(12.5)	0.568	0.451	3(3.1)	0.129	0.720
Multiple	04	0(0.0)			0(0.0)		
History of vaccination							
Yes	27	2(7.4)	0.739	0.390	1(3.7)	0.063	0.802
No	73	10(13.7)			2(2.7)		
Tattoo mark							

Zakari et. al.: Seroprevalence of hepatitis B and C co-infections among pregnant women attending Bingham UTH Jos

Yes	14	1(7.1)	0.364	0.546	1(7.1)	0.960	0.327
No	86	11(12.8)			2(2.3)		
Tribal mark							
Yes	14	1(7.1)	0.364	0.546	0(0.0)	0.503	0.478
No	86	11(12.8)			3(3.5)		

Key: HBV = Hepatitis B virus. HCV = Hepatitis C virus.

Table 4: Sero-prevalence of HBV and HCV Infection in relation to Educational Status among Pregnant Women

Education	No. screened	No. Positive (%)	HBV		HCV		
			χ^2	p-value	No Positive (%)	χ^2	p-value
No Formal	5	1(16.7)	5.259	0.262	0(0.0)	7.633	0.106
SSCE	6	5(22.7)			1(4.5)		
Pre-degree	22	0(0.0)			1(6.7)		
Degree	15	6(11.5)			0(0.0)		
Postgraduate	52	0(0.0)			1(20.0)		
Total	100	12(12.0)			3(3.0)		

Key: HBV = Hepatitis B virus, HCV = Hepatitis C virus.

Table 5: Sero-prevalence of HBV and HCV Infection in Relation to Occupation among Pregnant Women

Occupation	No. screened	No. Positive (%)	HBV		HCV		
			χ^2	p-value	No Positive (%)	χ^2	p-value
Civil servant	53	5(9.4)	8.192	0.146	3(5.7)	2.743	0.740
Business	30	5(16.7)			0(0.0)		
House wife	6	0(0.0)			0(0.0)		
Applicant	2	0(0.0)			0(0.0)		
Student	5	0(0.0)			0(0.0)		

Zakari et. al.: Seroprevalence of hepatitis B and C co-infections among pregnant women attending Bingham UTH Jos

Artisans	4	2(50.0)	0(0.0)
Total	100	12(12.0)	3(3.0)

Key: HBV = Hepatitis B virus. HCV = Hepatitis C virus

Table 6: Sero-prevalence of HBV and HCV Infection in Relation to Marital Status among Pregnant Women

Marital status	No. screened	No. Positive (%)	HBV		HCV	
			χ^2	p-value	No Positive (%)	χ^2 p-value
Married	97	12(12.4)	0.422	0.810	3(3.1)	0.096 0.953
Single	02	0(0.0)			0(0.0)	
Widow	01	0(0.0)			0(0.0)	
Total	100	12(12.0)			3(3.0)	

Key: HBV = Hepatitis B virus, HCV = Hepatitis C virus.

Table 7: Sero-prevalence of HBV and HCV Infection in Relation to Trimester among Pregnant Women

Marital status	No. screened	No. Positive (%)	HBV		HCV	
			χ^2	p-value	No. Positive (%)	χ^2 p-value
1 st Trimester	32	4(12.5)	0.042	0.979	0(0.0)	1.799 0.407
2 nd Trimester	32	4(12.5)			1(3.1)	
3 rd Trimester	36	4(11.1)			2(5.6)	
Total	100	12(12.0)			3(3.0)	

Key: HBV = Hepatitis B virus, HCV = Hepatitis C virus

A higher prevalence of HBV was found in the age groups 16-20 years and 21-25 years. The reason for the high prevalence among this age groups could be as a result of their frequency of

exposure to risk factors associated with the virus, as subjects within this age groups are still in their active sexual stage. In the present study, there was slightly decline in HBV seropositivity

with increasing age. Several studies have shown that HBV infection in pregnant women increases with age (Bertolini *et al.*, 2006. Papaevangelou *et al.*, 2008).

Reports in literature indicate that the chances of getting infection to infants are 10% when mother had an acute infection in first trimester; the prevalence increases to 90% if infection occurs in the third trimester (Onakewhor and Okonofua, 2008. Maheswari *et al.*, 2005). In this study, higher HBV positivity was found during the first and second trimester (12.5%) but association of trimesters with HBV positivity in this study was not statistically significant ($P > 0.05$). Lower prevalence of HBV was observed among those with higher educational attainment in the study population. This might be due to their socio-economic status and probably more knowledgeable on the preventive methods of the infection. We expected the singles and the widow to be more infected than the married because of the possibility of having more than one sexual partners as suggested by Onwuakore *et al.* (2014), but we had a contrary outcome. This difference could be adduced to the sample size and probably the married were more exposed to contaminated transfusion blood, instruments and surfaces in labour rooms.

The 3% prevalence of HCV in the tested population was higher compared with the report of Olubayo *et al.*, (2014) who reported 1% prevalence of HCV among pregnant women. Olaitan and Zamani (2010) had also reported 1% prevalence of Hepatitis C virus in ante-natal patients in Gwagwalada-Abuja, Nigeria and 2.5% was found in Maiduguri (Baba *et al.*, 1999). Sample size, screening methods as well as quality of the studies might be the reason for this variation

Risk factors to hepatitis B and C considered in the study were majorly history of blood transfusion multiple sex partners, history of vaccination and tattoo mark, even though, there was no statistical association ($p > 0.05$). This is in contrast with the work of Ephraim *et al.*, (2015) who stated that there exist a significant

association between HCV and the associated risk factors. The result is also in contrast to the report of Bala *et al.*, (2012) who revealed a significant association between HCV and blood transfusion, sharing of syringe and needles as well as consumption of alcohol as risk factors. The difference could be attributed to the geographical differences and possibly due to sample size.

CONCLUSION AND RECOMMENDATION

The study has shown that hepatitis B and C infections are still prevalent among pregnant women in the study area but hepatitis C recorded a low prevalence of 3.0% as compared to 12.0% recorded for HBV. However, it is recommended that, routine testing for HBV and HCV should be incorporated for pregnant women at first prenatal and postnatal visit so that HBV and HCV positive mothers can receive prompt intervention. National surveillance and enlightenment should be carried out to inform the public and especially the pregnant women about epidemiologic factors and possible risk factors necessitating the spread of the infections.

REFERENCES

- Baba, M.M., Onwuka, I.S. and Baba, S.S. (1999). Hepatitis B and C virus infections among pregnant women in Maiduguri, Nigeria. *Central European Journal of Public Health*, 7(2): 60-62.
- Bala, J.A., Kawo, A.H., Mukhtar, M.D., Sarki, A., Magaji, I.A. and Sani, M.N. (2012). Prevalence of hepatitis C virus infection among blood donors in some selected hospitals in Kano, Nigeria. *International Research Journal of Microbiology*, 3(6): 217-222.
- Bertolini, D.A., Pinho, J.R.R., Saraceni, C.P., Moreira, R.C., Granato, C.F.H. and Carrilho, F.J. (2006). Prevalence of serological markers of hepatitis B virus in pregnant women from Paraná State, Brazil. *Brazilian Journal of Medicine and Biology Research*, 39:1083-90.

- Cavallero. N.P., Santos. A.C., Melo. C.E., Morimitsu. S.R. and Barone. A.A. (2008). Hepatitis C virus detection in the serum of infected patients. *Brazilian Journal of Infections*, 12(5): 358-361.
- Chang. M.H. (2008). Hepatitis B virus infection. *Foetal, Neonatal Medicine*, 12: 160-167.
- Chien. Y.C., Jan. C.F., Kuo. H.S., Chen. C.J. (2006). Nationwide Hepatitis B Vaccination Program in Taiwan: Effectiveness in the 20 Years After It Was Launched. *Epidemiology Review*. 28: 126-35
- Collenberg. E., Ouedraogo. T., Ganame. J., Fickenscher. H., Kynast-Wolf. G., Becher. H., Kouyate. B., Krausslich. H.G., Sangare. L. and Tebit. D.M. (2006). Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: A comparative analysis. *Journal of Medical Virology*, 78(5):683-692.
- Eke. A.C., Eke, U.A., Okafor, C.I., Ezebielu. I.U and Ogbuagu, C. (2011). Prevalence correlates and pattern of hepatitis B surface antigen in a low resource setting. *Virology Journal*. 8:12.
- Ephrain.R., Donko. L., Sakyl. S.A., Ampong. J and Agbodjakey. H. (2015). Seroprevalence and risk factors of HBV and HCV infections among pregnant women in the Ashante. Akin North Municipality of the Ashanti region. Ghana: a cross sectional study *African Health Science Journal*. 15(3):709-713.
- Esan. A.J., Omisakin. C.T., Ojo-Bola. T., Owoseni. M.F., Fasakin. K.A. and Ogunleye. A.A. (2014). Sero-prevalence of Hepatitis B and Hepatitis C virus co-infection among pregnant women in Nigeria *American Journal of Biomedical Research*, 2(1): 11-15.
- Isa. M.a., Anija. E and Ali. M.A. (2016). Serological evidence of HCV antibodies among students attending university of Maiduguri medical centre. Borno State. Nigeria. *International Journal of Advanced Research in Biological Sciences*. 3(6):187-191.
- Kenebradikumo. P. and Isa. I. (2013). Seroprevalence of Hepatitis B surface antigen and anti-hepatitis C antibody among women attending antenatal clinic at a tertiary health facility in the Niger Delta of Nigeria. *Global advance Research Journal of Medicine and Medical Sciences*. 2(1): 6-12.
- Kramvis. A. and Kew. M. (2007). Epidemiology of hepatitis B virus in Africa. its genotypes and clinical associations of genotypes *Hepatology Research*, 37 (1): 9-19.
- Levy. M. and Koren. G. (1991). Hepatitis B vaccine in pregnancy: Maternal and fetal safety. *American Perinatal Journal*. 8:227-232.
- Liu. Z. and Hou. J. (2006). Hepatitis B virus (HBV) and Hepatitis C virus (HCV) dual infection. *International Journal of Medical Sciences*, 3:57-62.
- Luka. S.A., Ibrahim. M.B. and Iliya. S.N. (2008). Seroprevalence of hepatitis B surface antigen among pregnant women attending Ahmadu Bello University Teaching hospital. Zaria. Nigeria. *Nigerian Journal of Parasitology*, 29(1): 38-41.
- Maheswari. R T., Devi. S.R., Shendy. K.T. and Sathivathy. N. (2005). Markers of Viral hepatitis in pregnancy. *Indian Journal of Gastroenterology*. 4(2): 77-79.
- Mbaawuaga. E.M., Enenebeaku. M.N., Okopi. J.A. and Damen. J.G. (2008). Hepatitis B Virus (HBV) Infection among Pregnant Women in Makurdi. Nigeria. *African Journal of Biomedical Research*, 11: 155-159.
- Musa. B.M., Bussel. M.M., Samaila. A.A and Femi. K. (2015). Prevalence of HBV infection in Nigeria: 2000-2013. *Nigerian Journal of Clinical Practice*. 18(2):163-172.
- Oladeinde. B.H., Omoregie. R. and Oladeinde. O.B. (2013). Prevalence of HIV, HBV, and HCV infections among pregnant women

Zakari et. al.: Seroprevalence of hepatitis B and C co-infections among pregnant women attending Bingham UTH Jos

receiving antenatal care in a traditional birth home in Benin City, Nigeria. *Saudi Journal of Health sciences*. 2(2):113-117.

- Olaitan. A.O. and Zamani. L.G. (2010). Prevalence of hepatitis B virus and hepatitis C virus in ante-natal patients in Gwagwalada-Abuja, Nigeria. *Report and Opinion*, 2(7): 48-50.
- Oluboyo, B.O., Ugochukwu, V.I., Oluboyo, A.O., Ihim. A.C., Chukwuma. G.O., Ogenyi. S.I. and Onyemelukwe. A. (2014). Prevalence of hepatitis B and C viral infection in pregnant women attending antenatal clinic in Nnewi, Nigeria. *European Scientific Journal*, 10(3): 434-441.
- Onakewhor. J.U.E. and Okonofua F.E. (2008). Seroprevalence of hepatitis B surface antigen (HBsAg) in a tertiary health facility in Nigeria. *Journal of Obstetrics and Gynaecology*, 21: 583-86.
- Onwuakor. C.E., Eze.V.C., Nwankwo. I.U. and Iwu. J.O. (2014). Sero-prevalence of Hepatitis B Surface Antigen (HBsAg) amongst Pregnant Women Attending Antenatal Clinic at the Federal Medical Centre Umuahia, Abia State, Nigeria. *American Journal of Public Health Research* 2(6): 255-259.
- Otegbayo JA, Fasola FO, Abaja A. (2003). Prevalence of Hepatitis B surface antigen (HBsAg) and Hepatitis B envelope antigens (HBeAg), risk factors of viral acquisition and transaminase among blood donors in Ibadan, Nigeria. *Tropical Gastroenteritis*; 24:217-226.
- Papaevangelou. G., Farmaki. G. and Kada. H. (2008). Hepatitis B maternal-fetal transmission in Southern Europe. *Intervirology*, 41:197-200.
- Polyak. P. (2006). Innate intracellular defence against HIV and its modulation by HCV gene product. Postgraduate Course. *Vienna*. 30-33.
- Pungpapong. S., Kim. W.R. and Poterucha J.J. (2007). Natural History of Hepatitis B Virus Infection: An Update for Clinicians. *Mayo Clinical Procedures*, 82: 967-975.
- Samuel. D., Muller. R. and Alexande. G. (2004). Educational Research. National Hepatitis B Virus Programme. *Infectious Diseases*, 234: 221-332.
- Ugbebor.O., Aigbirior.M., Osazuwa.F., Enabudoso.E and Zabayo.O. (2011). The prevalence of hepatitis B and C viral infections among pregnant women. *North American Journal of medical sciences*, 3(5):238-241.
- Willey. J.M., Sherwood. L.M., Woolverton. C.J. (2008). Presscott, Harley and Kleins Microbiology 4th Ed. McGraw Hill Publishers. New York. 936-972.
- World Health Organization (2014) No Scientific Justification to Suspend Hepatitis B Immunization. Press release WHO. Accessed April. 2016. at <http://www.who.int/inf-fr-1998/en/pr98-67.htm>
- World Health Organization. (1999). Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, *Journal on Viral Hepatitis*, Antwerp, Belgium. 6:35-47.
- World Health Organization. (2011). Factsheet No 164.
- World Health Organisation. (2007) Hepatitis C estimated prevalence and number infected by world region. 2007. Accessed April 27, 2016. <http://www.who.int/mediacentre/factsheets/fs204/en>.
- Yakasai I.A, Ayyuba R, Abubakar I.S, Ibrahim S.A. (2012). Sero-prevalence of hepatitis B virus infection and its risk factors among pregnant women attending antenatal clinic at Aminu Kano Teaching Hospital, Kano, Nigeria. *Journal of Basic Clinical and Reproduction Science*, 1:49-55.